Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1735 | Thyroid (non-cancer) | ICEECE2012

Ischemic stroke without cardiac arrhythmia in a middle age female with thyrotoxicosis

Palermo C. , Torres O. , Martinez J. , Gonzalez E. , Miranda M. , Figueroa J. , Gonzalez J. , Silva F. , Kolodjiev F.

51 y/o female with past medical history of migraine headache, brought to UR because of hypoactivity, generalized weakness, confusion, lack of balance and dysarthria since one day of evolution. No medications. No Habits. Past history: negative for hypertension, cardiac disease or dyslipidemia. Physical examination: normal vital signs and weight. Alert, awake, and oriented only in person. Palpable nontender left thyroid lobe. Bilateral hyperreflexia.Labs: ...

ea0028p134 | Growth and development | SFEBES2012

Growth hormone (gh)-transgenic mice exhibit gh-stat5 insensitivity associated with up-regulation of negative signaling modulators

Martinez Carolina , Piazza Veronica , Miquet Johanna , Ramirez Maria , Becu-Villalobos Damasia , Bartke Andrzej , Turyn Daniel , Sotelo Ana

JAK2/STAT5 is the principal growth hormone (GH) signaling pathway related to body growth. It is positively regulated by glucocorticoid receptor (GR) and hepatocyte nuclear factor 1 (HNF-1) and downregulated by activation of tyrosine-phosphatases SHP-1,-2 and PTP-1B, and by GH-induction of suppressors of cytokine signaling (CIS/SOCS) that block GHR or JAK2, and promote internalization/degradation of signaling complexes. This pathway is desensitized in liver of adult transgenic ...

ea0024oc1.7 | Oral Communications 1 | BSPED2010

Best Abstract Winner

Gaston-Massuet Carles , Andoniadou Cynthia , Signore Massimo , Jayakody Sujatha , Charolidi Nocoletta , Tissier Paul Le , Dattani Mehul , Martinez-Barbera Juan Pedro

Wnt/beta-catenin signalling pathway is required during embryonic development for normal cell proliferation, differentiation and for organ homeostasis in adulthood. Over-activation of this pathway has been implicated in human cancers such as colon or skin cancers. Here, we demonstrate that enhancement of the Wnt pathway in the embryonic Rathke’s pouch causes over-proliferation of progenitor cells and severe differentiation defects in the Pit1-lineage, which results ...

ea0023oc4.2 | Oral Communications 4 | BSPED2009

First report of a de novo heterozygous SOX2 deletion associated with a large hypothalamo-pituitary tumour gives further insights into the role of SOX2 in pituitary development.

Alatzoglou Kyriaki S , Arriazu Maria Cristina , Crolla John , Martinez-Barbera Juan Pedro , Roubicek Martin , Dattani Mehul T

Background: SOX2 is a member of the SOX family of transcription factors (SRY-related high-mobility group (HMG) box). Heterozygous, de novo, loss-of-function mutations were initially reported in patients with bilateral anophthalmia/microphthalmia, developmental delay, male genital tract abnormalities, oesophageal atresia and sensorineural hearing loss. We have recently reported a number of SOX2 mutations in patients with anterior pituitary hypoplasia and hy...

ea0022p435 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Molecular analysis of tumor tissue enabled selection of a successful combined therapy of somatostatin and dopamine agonists in a case of TSH-secreting pituitary adenoma

Quintero Ana , Galvez-Moreno M Angeles , Jimenez-Reina Luis , Martinez-Fuentes Antonio J , Benito-Lopez Pedro , Castano Justo P

TSH-secreting pituitary adenomas (thyrotropinomas or TSH-omas) are rare. At diagnosis, TSH-omas are frequently macroadenomas presenting with variable symptoms, and signs of hyperthyroidism. Somatostatin analogs (SSA) are a very efficient treatment to improve clinical signs in patients with TSH-omas, reducing hormone levels (90%) and causing tumor shrinkage (50%).Inhibitory effects of SSA are mediated by a family of five somatostatin receptor subtypes (sst1-5), with sst2 and ss...

ea0021p220 | Endocrine tumours and neoplasia | SFEBES2009

First report of SOX2 loss of function associated with a large hypothalamo-pituitary tumour; further insights into the role of SOX2 in pituitary development

Alatzoglou Kyriaki S , Arriazu Maria Cristina , Crolla John , Martinez-Barbera Juan Pedro , Roubicek Martin , Buchanan Charles , Dattani Mehul T

Background: SOX2 is a member of the SOX family of transcription factors (SRY-related high-mobility group (HMG) box). Heterozygous, de novo, loss-of-function mutations were initially reported in patients with bilateral anophthalmia/microphthalmia, developmental delay, male genital tract abnormalities, oesophageal atresia and sensorineural hearing loss. We have recently reported a number of SOX2 mutations in patients with anterior pituitary hypoplasia and hy...

ea0020p33 | Adrenal | ECE2009

A multi-institutional audit of laparoscopic adrenalectomy in Greece and the UK

Kekis Panagiotis , Markogiannakis Haridimos , Michalopoulos Nikolaos , Lagoudianakis Emmanuel , Fleming Bill , Martinez-Isla Alberto , Lynn John , Manouras Andreas

Objective: To evaluate the results of laparoscopic adrenalectomy in our institutions.Methods: Prospectively collected data from 2000 to 2007.Results: During the 8-year study period, 160 laparoscopic adrenalectomies were performed in 150 patients. Mean age was 49.8 years (female: 60.7%). Twenty-seven patients (18%) had previous open abdominal operations. There were 10 bilateral (6.6%) for Cushing’s disease, 64 right (42.7%) and...

ea0020p412 | Diabetes and Cardiovascular | ECE2009

Clinical characteristics and mother-fetal results in patients with gestational diabetes

Morales Cristobal , Martinez de Pinillos Guillermo , Garcia-Quiros Juan M , Tome Monica , Fernandez Ignacio , Serrano Isabel , Sendon Angel

Objective: To evaluate the main clinical characteristics and the obstetrical results of perinatal morbi-mortality of women with gestacional diabetes in our Service.Material and method: We made a descriptive study of 83 gestational diabetes patients which became a pursuit coordinated between the services of Endocrinology and Gynecology. The following main aspects were analyzed: age, toxic habits, BMI pre-gestational, first pregnancy or not, previous antec...

ea0020p434 | Diabetes and Cardiovascular | ECE2009

Insulin treatment intensification in daily diabetes hospital

Garcia-Quiros Juan M , Morales Cristobal , Serrano Isabel , Martinez de Pinillos Guillermo , Tome Monica , Fernandez Ignacio , Sendon Angel

Objectives: To verify the results of the insulin treatment intensification in the control of Diabetes Mellitus type 1 and 2 (DM1 and DM2).Methodology: Of 100 diabetic patients (30% DM1 and 70%DM2) derived to Day Diabetes Hospital (DDH) by glycemic decompensation during year 2007 were studied, 45% women and 55% men (we excluded the debut). The average age of the patients was of 35.1 years in DM1 and 64.4 years in DM2. The Hba1c in the first visit and to t...

ea0016p165 | Comparative endocrinology | ECE2008

Chemokine CXCL10 gene polymorphisms in Addison's disease

Sadet Dilek , Penna-Martinez Marissa , Kurylowicz Alina , Paunkovic Jane , Kahles Heinrich , Bruck Patrick , Badenhoop Klaus , Ramos-Lopez Elizabeth

Background and aims: CXC chemokine ligand 10 (CXCL10) also known as chemokine interferon γ inducible protein (IP-10) is a CXCR3 chemokine belongs to a group of structurally related molecules, that induce the chemotaxis of diverse leukocyte subtypes including activated T-helper 1 lymphocytes, natural killer cells and monocytes. In patients with Hashimoto’s thyroiditis, type 1 diabetes mellitus and Graves’ disease high levels of CXCL10 ligand in serum have been fo...